This is a Phase 2 clinical trial that multicenter. The topic is pegylated liposomal doxorubicin plus non-pegylated paclitaxel in treating unresectable or advanced malignant vascular tumors. This is a Phase 2 clinical trial conducted multicenter. And because we know that malignant vascular tumors remain associated with a very poor prognosis, progression-free survival is very short, and the overall response rate is very low...
This is a Phase 2 clinical trial that multicenter. The topic is pegylated liposomal doxorubicin plus non-pegylated paclitaxel in treating unresectable or advanced malignant vascular tumors. This is a Phase 2 clinical trial conducted multicenter. And because we know that malignant vascular tumors remain associated with a very poor prognosis, progression-free survival is very short, and the overall response rate is very low. So, okay. So we can see that the ORR for anthracyclines is only 20% to 30%, and the ORR for non-pegylated paclitaxel is only 30%. So the ORR is very low. So we are facing treatment options with very low response rates. And the progression-free survival for doxorubicin and paclitaxel is very short, only four months. Progression-free survival is very short. So we need better treatment. So there is an unmet need for treating radiation-induced sarcoma. So we use the combination of the two drugs. Pegylated liposomal doxorubicin can prolong circulation time, increase drug accumulation at the tumor site, and reduce cardiotoxicity, and non-pegylated paclitaxel could increase drug delivery and reduce toxicity. So this combination of the two drugs could increase tumor control, improve drug delivery, and reduce cardiac toxicity. So this is the first Phase 2 clinical trial. And we can see that the aim is to evaluate safety and efficacy. So the dose of doxorubicin is 35 mg/m², and the dose for non-pegylated paclitaxel is 220 mg. So the primary endpoint is ORR, and the secondary endpoints are DCR, PFS, and OS. From that, we can see that the ORR for the cohort is about 50%. The ORR for angiosarcoma is 31.3%, and PFS for the cohort is about eight months. And interestingly, we can see that PFS for angiosarcoma is about 7.3 months. So we can see that this combination achieved an ORR of 50%, or even higher. So from that, we can see that this combination of these two drugs can achieve a higher ORR and longer progression-free survival. So we can see that overall survival is about 28 months. So with the combination of the two drugs, we can achieve a higher ORR of 50%. So from that, in the future, we can plan randomized clinical trials of this combination.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.